412 related articles for article (PubMed ID: 15522036)
21. Antibacterial discovery and development--the failure of success?
Fernandes P
Nat Biotechnol; 2006 Dec; 24(12):1497-503. PubMed ID: 17160049
[TBL] [Abstract][Full Text] [Related]
22. [Current challenges for the pharmaceutical research industry].
Chalchat B
Ann Pharm Fr; 1993; 51(1):16-25. PubMed ID: 8215118
[TBL] [Abstract][Full Text] [Related]
23. Transforming the work of early-stage drug discovery through bioprocess informatics.
Holzman TF; Hebert EJ
Drug Discov Today; 2005 Jan; 10(1):61-7. PubMed ID: 15676300
[TBL] [Abstract][Full Text] [Related]
24. Venturing into drug discovery.
Steinmetz M
Nat Biotechnol; 1998 May; 16 Suppl():17. PubMed ID: 9591255
[No Abstract] [Full Text] [Related]
25. The antibacterial drugs market.
Kresse H; Belsey MJ; Rovini H
Nat Rev Drug Discov; 2007 Jan; 6(1):19-20. PubMed ID: 17269159
[No Abstract] [Full Text] [Related]
26. The future of natural products as a source of new antibiotics.
Luzhetskyy A; Pelzer S; Bechthold A
Curr Opin Investig Drugs; 2007 Aug; 8(8):608-13. PubMed ID: 17668363
[TBL] [Abstract][Full Text] [Related]
27. The urgent need for new antibacterial agents.
Wise R;
J Antimicrob Chemother; 2011 Sep; 66(9):1939-40. PubMed ID: 21700627
[No Abstract] [Full Text] [Related]
28. Natural products--the future scaffolds for novel antibiotics?
Butler MS; Buss AD
Biochem Pharmacol; 2006 Mar; 71(7):919-29. PubMed ID: 16289393
[TBL] [Abstract][Full Text] [Related]
29. Opportunities and challenges in the discovery of new central nervous system drugs.
Krause JE; Chenard BL
Ann N Y Acad Sci; 2008 Nov; 1144():243-50. PubMed ID: 19076381
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial drug development--the past, the present, and the future.
Powers JH
Clin Microbiol Infect; 2004 Nov; 10 Suppl 4():23-31. PubMed ID: 15522037
[TBL] [Abstract][Full Text] [Related]
31. Timely synthetic support for medicinal chemists.
Potoski J
Drug Discov Today; 2005 Jan; 10(2):115-20. PubMed ID: 15718160
[TBL] [Abstract][Full Text] [Related]
32. Opinion: anticipating change in drug development: the emerging era of translational medicine and therapeutics.
Fitzgerald GA
Nat Rev Drug Discov; 2005 Oct; 4(10):815-8. PubMed ID: 16224453
[TBL] [Abstract][Full Text] [Related]
33. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
Bjerrum OJ
Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
[TBL] [Abstract][Full Text] [Related]
34. The role of the pharmaceutical industry in meeting the public health threat of antibacterial resistance.
Bergström R
Drug Resist Updat; 2011 Apr; 14(2):77-8. PubMed ID: 21493123
[TBL] [Abstract][Full Text] [Related]
35. Brazil: An emerging partner in drug R&D.
Rodrigues DG
IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
[TBL] [Abstract][Full Text] [Related]
36. In silico drug discovery: tools for bridging the NCE gap.
Larvol BL; Wilkerson LJ
Nat Biotechnol; 1998 May; 16 Suppl():33-4. PubMed ID: 9591262
[No Abstract] [Full Text] [Related]
37. The value of drug repositioning in the current pharmaceutical market.
Tobinick EL
Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
[TBL] [Abstract][Full Text] [Related]
38. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
Bax R; Green S
J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
[TBL] [Abstract][Full Text] [Related]
39. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
40. The future challenges facing the development of new antimicrobial drugs.
Coates A; Hu Y; Bax R; Page C
Nat Rev Drug Discov; 2002 Nov; 1(11):895-910. PubMed ID: 12415249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
